• NU6300’s Selective Inhibition of Gasdermin D: Mechanistic Ad

  2026-04-21

  Jiang et al. identify NU6300 as a covalent inhibitor targeting cysteine-191 of gasdermin D (GSDMD), thereby blocking its cleavage and palmitoylation. This work illuminates a new mechanism for regulating pyroptosis and highlights GSDMD as a promising therapeutic target for inflammatory diseases.

• Demethyleneberberine: Applied Workflows in Neurodegeneration

  2026-04-20

  Demethyleneberberine (DMB) is redefining neuroinflammation and cancer research with its multi-pathway inhibition and high reproducibility. This guide translates bench evidence into robust workflows, troubleshooting insights, and next-stage applications for DMB in translational disease modeling.

• Applied Use-Cases for GSK-923295: Precision CENP-E Inhibitio

  2026-04-20

  GSK-923295 offers bench scientists a precise tool to dissect chromosome alignment regulation and induce targeted cell cycle arrest in mitosis. This guide translates the latest centromere biology into actionable workflows, troubleshooting advice, and comparative insights for advanced cancer research models.

• CX-5461: Applied Workflows for RNA Polymerase I Inhibition i

  2026-04-19

  CX-5461 stands out as a precision RNA polymerase I inhibitor for dissecting ribosome biogenesis and inducing autophagy or senescence in solid tumor models. This article delivers practical protocols, advanced troubleshooting, and direct insights from the latest evidence—empowering cancer researchers to optimize experimental outcomes using APExBIO’s trusted reagent.

• Strategic Senescence Detection: Advancing Translational Impa

  2026-04-18

  Explore how the Cell Senescence β-Galactosidase Staining Kit empowers translational researchers to bridge mechanistic senescence insights with actionable assay strategy—fueling innovation in aging biology, drug discovery, and therapeutic development. This article synthesizes evidence from contemporary senolytic research, protocol best practices, and workflow optimization to provide a credible, forward-looking guide that goes beyond standard product pages.

• Pazopanib (GW-786034): Multi-Targeted RTK Inhibition in Canc

  2026-04-17

  Pazopanib (GW-786034) is a potent, selective multi-targeted receptor tyrosine kinase inhibitor with robust efficacy for angiogenesis inhibition and tumor growth suppression in preclinical cancer research. Its activity profile and benchmark data support its use in models such as ATRX-deficient glioma and renal cell carcinoma. Supplied by APExBIO, Pazopanib demonstrates reproducible, high-specificity inhibition of VEGFR, PDGFR, and FGFR signaling.

• Inducing Embryonic Dormancy via mTOR Inhibition: Protocol Ad

  2026-04-16

  This protocol-based study presents a noninvasive, reproducible method to induce a diapause-like dormant state in mammalian embryos and pluripotent stem cells by pharmacologically inhibiting mTOR. The approach enables new exploration of molecular dormancy mechanisms and offers scalable alternatives to traditional, invasive models.

• Neuronal Glycogen Breakdown Mitigates Tauopathy via PPP Flux

  2026-04-15

  Bar et al. establish that impaired glycogen metabolism is a mechanistic hallmark of tauopathies such as Alzheimer’s disease. Their study demonstrates that enhancing neuronal glycogen breakdown redirects glucose through the pentose phosphate pathway, reducing oxidative stress and pathological tau accumulation. These findings illuminate metabolic intervention points for neurodegeneration research and assay development.

• MLF2 Suppresses p53 and Drives Colorectal Tumor Progression

  2026-04-14

  This article discusses the identification of MLF2 as a novel negative regulator of p53 in colorectal cancer, as reported by Fang et al. The study reveals that MLF2 inhibits USP7-mediated p53 stabilization, promoting tumorigenesis—providing new mechanistic insight with translational implications for cancer biology and experimental design.

• Nilotinib (AMN-107) in Kinase Signaling and CML Research

  2026-04-13

  Nilotinib (AMN-107) delivers potent, selective inhibition of BCR-ABL and KIT mutants, enabling precise dissection of tyrosine kinase signaling in chronic myeloid leukemia and gastrointestinal stromal tumor models. This guide translates recent structural insights and experimental best practices into actionable protocols and troubleshooting strategies for advanced cancer research.

• 5-Azacytidine in Epigenetic Cancer Research: Applied Workflo

  2026-04-12

  5-Azacytidine (5-AzaC) empowers researchers to demethylate DNA and reactivate silenced tumor suppressor genes, transforming both mechanistic and translational cancer studies. This article delivers hands-on protocol guidance, troubleshooting insights, and actionable lessons from landmark gastric cancer research, positioning APExBIO’s 5-Azacytidine as a gold-standard tool for epigenetic modulation.

• Selective Autophagy Regulates IRF3 Stability in Antiviral Im

  2026-04-12

  Wu et al. (2021) reveal that selective autophagy, mediated by cargo receptor CALCOCO2/NDP52 and modulated by deubiquitinase PSMD14, precisely controls IRF3 protein stability. This mechanism fine-tunes type I interferon production during antiviral responses, providing new insights into transcription factor regulation and immune homeostasis.

• SU5416 (Semaxanib): Precision Angiogenesis Inhibition for Re

  2026-04-11

  SU5416 (Semaxanib) delivers robust, selective VEGFR2 inhibition, enabling researchers to dissect angiogenesis and immune modulation in cancer, vascular, and pulmonary hypertension models. Advanced workflows, troubleshooting insights, and data-backed guidance ensure reproducibility and translational impact.

• Dronedarone (Multaq): Optimizing Cardiac Arrhythmia Research

  2026-04-11

  Dronedarone (Multaq) stands out as a high-purity, workflow-compatible antiarrhythmic agent for atrial fibrillation and flutter research. This guide delivers actionable experimental protocols, troubleshooting strategies, and evidence-driven insights that maximize reproducibility and data quality when using APExBIO’s dronedarone in advanced cardiac arrhythmia pharmacology studies.

• Gap26 Connexin 43 Mimetic Peptide: A Precise Gap Junction...

  2026-04-10

  Gap26, a connexin 43 mimetic peptide, is a validated, selective gap junction blocker peptide for dissecting intercellular signaling in neuroprotection and vascular research. Its precise inhibition of connexin 43 hemichannels and robust solubility make it an indispensable tool for calcium signaling modulation and ATP release inhibition studies.

452 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page